A pilot study in healthy volunteers and patients with glioblastoma – Measurement of AF, inflammatory markers and lipids after intake of AF-enhancing products
(2023) LÄKM05 20222MD Programme
- Abstract
- Background: Glioblastoma is the most common primary malignant brain tumor in adults. Elevated interstitial fluid pressure (IFP) within the tumor restricts drug uptake and contributes to the dismal prognosis. Antisecretory factor (AF) is an endogenous protein that possesses antisecretory and immunomodulating properties. In vivo, AF can reduce elevated IFP. There are two AF-enhancing products; Salovum and SPC-flakes. These are not classified as drugs, but as food supplements with medical benefits. Salovum is currently being investigated as add- on treatment for glioblastoma.
Aim: To investigate if we can measure changes in levels of AF and inflammatory markers in healthy volunteers and patients with glioblastoma after intake of Salovum or... (More) - Background: Glioblastoma is the most common primary malignant brain tumor in adults. Elevated interstitial fluid pressure (IFP) within the tumor restricts drug uptake and contributes to the dismal prognosis. Antisecretory factor (AF) is an endogenous protein that possesses antisecretory and immunomodulating properties. In vivo, AF can reduce elevated IFP. There are two AF-enhancing products; Salovum and SPC-flakes. These are not classified as drugs, but as food supplements with medical benefits. Salovum is currently being investigated as add- on treatment for glioblastoma.
Aim: To investigate if we can measure changes in levels of AF and inflammatory markers in healthy volunteers and patients with glioblastoma after intake of Salovum or SPC-flakes.
Methods: Venous blood samples from healthy volunteers (n=10) and patients with glioblastoma (n=8) who had consumed AF-enhancing products were obtained. The enzyme- linked immunosorbent assay (ELISA) was used to measure AF-levels. Inflammatory markers and the complement proteins C3a and C5a were analyzed with Meso Scale Discovery. Due to a small number of samples, no statistical calculations were made. Data was analyzed descriptively with Microsoft Excel.
Results: AF-levels were successfully measured with ELISA, but no significant increase in expression could be seen. AF-enhancing products affected the expression of several inflammatory markers in blood in healthy volunteers and patients with glioblastoma. The effect was most protruding in patients with ongoing inflammation. No general trends could be seen regarding levels of AF or inflammatory markers, but individual changes were noted.
Conclusion: No statistical calculations were made and hence no significant conclusions can be drawn. However, there are indications that AF-enhancing products affect the expression of several cytokines and modulate inflammation. The selected methods were able to measure desired markers, but larger studies and alternative analysis methods are necessary to confirm biological effects induced by AF. Hopefully, our study provides an insight into AF’s role and contributes to future studies regarding glioblastoma. (Less)
Please use this url to cite or link to this publication:
http://lup.lub.lu.se/student-papers/record/9155003
- author
- El-Sabee, Hanin Fabiana LU
- supervisor
-
- Anna Darabi LU
- organization
- course
- LÄKM05 20222
- year
- 2023
- type
- H2 - Master's Degree (Two Years)
- subject
- keywords
- Glioblastoma Antisecretory factor Immunomodulation
- language
- English
- id
- 9155003
- date added to LUP
- 2025-03-10 09:42:16
- date last changed
- 2025-03-10 09:42:16
@misc{9155003,
abstract = {{Background: Glioblastoma is the most common primary malignant brain tumor in adults. Elevated interstitial fluid pressure (IFP) within the tumor restricts drug uptake and contributes to the dismal prognosis. Antisecretory factor (AF) is an endogenous protein that possesses antisecretory and immunomodulating properties. In vivo, AF can reduce elevated IFP. There are two AF-enhancing products; Salovum and SPC-flakes. These are not classified as drugs, but as food supplements with medical benefits. Salovum is currently being investigated as add- on treatment for glioblastoma.
Aim: To investigate if we can measure changes in levels of AF and inflammatory markers in healthy volunteers and patients with glioblastoma after intake of Salovum or SPC-flakes.
Methods: Venous blood samples from healthy volunteers (n=10) and patients with glioblastoma (n=8) who had consumed AF-enhancing products were obtained. The enzyme- linked immunosorbent assay (ELISA) was used to measure AF-levels. Inflammatory markers and the complement proteins C3a and C5a were analyzed with Meso Scale Discovery. Due to a small number of samples, no statistical calculations were made. Data was analyzed descriptively with Microsoft Excel.
Results: AF-levels were successfully measured with ELISA, but no significant increase in expression could be seen. AF-enhancing products affected the expression of several inflammatory markers in blood in healthy volunteers and patients with glioblastoma. The effect was most protruding in patients with ongoing inflammation. No general trends could be seen regarding levels of AF or inflammatory markers, but individual changes were noted.
Conclusion: No statistical calculations were made and hence no significant conclusions can be drawn. However, there are indications that AF-enhancing products affect the expression of several cytokines and modulate inflammation. The selected methods were able to measure desired markers, but larger studies and alternative analysis methods are necessary to confirm biological effects induced by AF. Hopefully, our study provides an insight into AF’s role and contributes to future studies regarding glioblastoma.}},
author = {{El-Sabee, Hanin Fabiana}},
language = {{eng}},
note = {{Student Paper}},
title = {{A pilot study in healthy volunteers and patients with glioblastoma – Measurement of AF, inflammatory markers and lipids after intake of AF-enhancing products}},
year = {{2023}},
}